All In Biotech

Drug Trial Radar · NCT03866369

Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose

A Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Volunteers in Order to Define Lanifibranor (IVA337) Supra-therapeutic Dose in a Multiple Dosing Regimen

Last checked: Nov 19, 2026Latest source record: Nov 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Jan 17, 2019

Primary completion

Aug 27, 2019

Study completion Aug 27, 2019

Sponsor

Lead sponsor
Inventiva PharmaIndustry
Sponsor type
Industry
Collaborators
Parexel
First posted
Mar 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will be a double-blind, randomized, placebo-controlled, multiple ascending dose study with lanifibranor. The study will consist of up to 3 cohorts of 12 subjects each; therefore, approximately 36 subjects will be included in this study.

Conditions

  • Healthy Subjects

Interventions

  • MoxifloxacinDrug

    Single oral dose at D-8

  • PlaceboDrug

    Single oral dose at D-1

  • LanifibranorDrug

    Single daily oral dose during 14 days

  • PlaceboDrug

    Single daily oral dose during 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse eventsTime frame: From Baseline up to 15 days
  2. Number of abnormal Vital signs (blood pressure, pulse) and physical examsTime frame: From Baseline up to 15 days
  3. Number of abnormal Clinical laboratory tests (chemistry, hematology, urinalysis)Time frame: From Baseline up to 15 days
  4. Number of abnormal 12-lead digital electrocardiograms parameters (Heart rate, QT/QTc interval, PR interval, QRS interval, RR interval) change from baselineTime frame: From Baseline up to 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International GmbH

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.